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Hereditary lymphedema is a chronic swelling of limbs due to dysfunction of lymphatic vessels. An autosomal
dominant, congenital form of the disease, also known as “Milroy disease,” has been mapped to the telomeric part
of chromosome 5q, in the region 5q34-q35. This region contains a good candidate gene for the disease, VEGFR3
(FLT4), that encodes a receptor tyrosine kinase specific for lymphatic vessels. To clarify the role of VEGFR3 in
the etiology of the disease, we have analyzed a family with hereditary lymphedema. We show linkage of the disease
with markers in 5q34-q35, including a VEGFR3 intragenic polymorphism, and we describe an ArG transition
that cosegregates with the disease, corresponding to a histidine-to-arginine substitution in the catalytic loop of the
protein. In addition, we show, by in vitro expression, that this mutation inhibits the autophosphorylation of the
receptor. Thus, defective VEGFR3 signaling seems to be the cause of congenital hereditary lymphedema linked to
5q34-q35.
Introduction
Lymphedema is caused by a dysfunction of the lymphatic
system. Lymphangiography demonstrates hypoplasia or
aplasia of lymphatic channels (Kinmonth 1982). It pro-
vokes disfiguration and disabling swelling, mostly local-
ized at the extremities (Esterly 1965). Familial lymphed-
ema, usually segregating as an autosomal dominant trait,
can be classified according to the age at onset, as early-
onset lymphedema (primary congenital lymphedema or
Milroy disease [MIM 153100]) or late-onset lymphedema
(lymphedema praecox or Meige lymphedema [MIM
153200]). Lymphedema can also occur in associationwith
other clinical features (e.g., autosomal dominant lym-
phedema with distichiasis that has been linked to 16q24.3
[MIM 153400]), or as a component of a syndrome (e.g.,
Turner or Noonan syndrome [MIM 163950]).
Linkage between early-onset lymphedema and mark-
ers in the telomeric part of chromosome 5q (5q34-q35)
has been demonstrated for four families in one study
(Ferrell et al. 1998). In another study, linkage with
5q35.3 has been demonstrated in five families, including
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one large four-generation family (Evans et al. 1999).
The vascular endothelial growth factor receptor-3
(VEGFR3, FLT4) gene, located in this region, is a strong
candidate for being causative because of its importance
in lymphatic vessels. The gene is expressed in all vessels
early during embryogenesis, and, thereafter, expression
is limited to the developing and adult lymphatic vessels
(Kaipainen et al. 1995). Disruption of Vegfr3 in mice
leads to embryonic death at day 9.5 due to defective
development of large blood vessels and cardiovascular
failure (Dumont et al. 1998). Moreover, cutaneous ov-
erexpression of its ligand, vascular endothelial growth
factor C (VEGFC), induces selective hyperplasia of the
lymphatic vasculature (Jeltsch et al. 1997). A leucine
for proline substitution (P1114L) has been detected in
the VEGFR3 protein in one family with lymphedema
(Ferrell et al. 1998). However, this family was too small
to be informative for linkage, and no other putative
mutation was detected in the four families sharing link-
age to this region.
We describe a two-generation family with five indi-
viduals affected by congenital hereditary lymphedema,
show linkage between the phenotype and markers in
the 5q34-q35 region, and describe an H1035R substi-
tution in a highly conserved residue in the catalytic loop
of the VEGFR3 receptor. In addition, we show by in
vitro expression studies that this amino acid substitution
causes loss of VEGFR3 tyrosine kinase activity. Thus,
defective VEGFR3 signaling is responsible for 5q34-
q35–linked lymphedema.
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Figure 1 A, Pedigree of the family with inherited congenital
lymphedema. Blackened symbols represent affected individuals.B,De-
duced haplotypes for three markers in 5q34-35. FLT4I, VEGFR3 in-
tragenic polymorphism. Haplotype transmitted with disorder is boxed.
C, Autoradiogram of the intragenic FLT4I marker. D, Allele-specific
PCR for the A3123G mutation. Lower band, mutated allele. Upper
band, internal control for PCR.
Subjects and Methods
Family
Congenital lymphedema had been identified in all five
affected family members (fig. 1A), and thus the family
had been referred to a genetic counselor (K.D.). The fa-
ther, individual I.1, had bilateral congenital lymphedema
and frequent erysipelas. Individual II.2 had bilateral con-
genital lymphedema of the feet, more pronounced on the
right side and not present above the ankles. Prominent
veins were observed on the lower limbs. Individual II.3
had congenital lymphedema, limited to the dorsum of the
right foot, and prominent left pretibial vein. Individual
II.5 had bilateral congenital lymphedema involving the
lower limbs below the knee. Individual II.7 had bilateral
congenital lymphedema of the feet, extending to the lower
part of the lower limbs. She was born at 32 weeks, with
premature rupture of the membranes; hyalinic membrane
disease, grade II; hyperbilirubinism; and transient hyper-
phenylalaninemia, probably unrelated to the disorder. In
addition, the affected children (subjects II.2, II.3, II.5, and
II.7) had flat, broad nasal bridges and epicanthic folds.
This was not obvious in their affected father. Venous
blood samples were drawn after informed consent was
obtained from all family members, as approved by the
ethics committee of Katholieke Universiteit Leuven.
Linkage Analysis
Genomic DNA was extracted from buffy coats
(QIAamp DNA Blood Mini Kit [Qiagen]). Individuals
were genotyped as described elsewhere (Boon et al. 1994).
For linkage analyses, we used microsatellite markers
D5S1354 and D5S2006, located in the VEGFR3 region
(Ferrell et al. 1998), as well as an intragenic polymor-
phism of the VEGFR3 gene (detectable by primers FLT4-
CA-F: 5′-CCTTGGGCAAGTCGTGGC-3′ and FLT4-CA-
R: 5′-GAGAGAGACTCCATCAGG-3′ (Ferrell et al.
1998). Linkage analyses were performed with autosomal
dominant mode of inheritance, either 100% or 90% pen-
etrance, a disease allele frequency of 1/10,000, and equal
allele frequencies for markers. Calculations were per-
formed with Linkage Package version 5.1 (Lathrop et al.
1984).
VEGFR3 Gene Analysis
To screen part of the VEGFR3 gene encoding the in-
tracellular kinase domain for mutations by SSCP and het-
eroduplex analyses, primers (synthesized by Gibco BRL)
were designed on the basis of intronic sequences (K. Iljin,
M. J. Karkkainen, E. C. Lawrence, M. A. Kimak, M.
Uutela, J. Taipale, R. E. Ferrell, and K. Alitalo, unpub-
lished data). The primer sequences (from 5′ to 3′) are
as follows: FLT4I-1: CAACCCAGTCAGCTCCTTC,
FLT4I-2: ACCTGTCTCCACGCTCACC, FLT4I-3: CT-
GCTCCTCACCAGCTAGG, FLT4I-4: GAACGGGGA-
CCTGCCAGG, FLT4I-5: GGGGTCTCGCCGTCCC-
AG, FLT4I-6: CGGGTGCAAACGCGGAGC, FLT4I-7:
GCAGAGGCGCCTCCATTCC, FLT4I-8: TCTGCGG-
CGGACGACTGG, FLT4I-9: GGCCCGTCAGGCAC-
TTGG, FLT4I-10: CCTGGGGCTGGGTAGATGG,
FLT4I-11: GTGGGGATGCACCCTTTTCC, FLT4I-12:
TATTACCCCAGGGGCCTGC, FLT4I-13: TCACCT-
GTTCCGCCCCACG, FLT4I-14: TCCCTCCGTCTCC-
CCATCC, FLT4I-15: CGCTTGCTGTCCCCAAAACC,
FLT4I-16: ACGGGGGTGGGGTGCATG, FLT4I-17:
CAGGGGCCAAAGGCCATAG, FLT4I-18: CAGTGG-
CTGGTGGTTTCTGG, FLT4I-19: GCTTTCTCCCAC-
CCTACTCC, FLT4I-20: GCTGCAGCGCGTTCCTCA-
G, FLT4I-21: CAGCCCTGAGCCGAGAGC, FLT4I-22:
TGCAGGAGGGCCTCAGGC, FLT4I-23: AGGGCA-
ACATCGATACCTGC, FLT4I-24: CTGGCCACGTGG-
GCGCTG. Primers were end-labeled with 32P, using poly-
nucleotide kinase (Takara) and g[32P]-ATP (Amersham
Pharmacia Biotech), and were used to amplify exons
16–27 (according to the numbering of Iljin et al., unpub-
lished data). These exons encode the intracellular part of
the receptor. Only genomic DNA was available from this
family, and thus only the intracellular part of VEGFR3,
for which the exon-intron structure had been identified,
was examined. The PCRs were performed in a volume of
20 ml as described by Boon et al. (1999), with the fol-
lowing cycling conditions: 95C for 5 min; 32 cycles of
94C for 30 s, 60C for 30 s, and 72C for 30 s; and 72C
for 10 min. The size of the amplification products varied
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between 184 and 241 bp. The PCR reactionswere divided
into two aliquots before loading onto nondenaturing
polyacrylamide gels (MDE Mutation Detection gel so-
lution, FMC BioProducts). EDTA (final concentration, 5
mM) and nondenaturing loading buffer (according to
FMC) were added to the reactions for heteroduplex anal-
ysis, whereas a denaturing loading buffer (according to
FMC) was added to the SSCP samples. After heat de-
naturation, the samples for SSCP analysis were immedi-
ately loaded onto SSCP gels. The samples for heterodu-
plex analysis were first cooled from 95C to 37C at 1C/
min, to increase the formation of heteroduplexes. Both
gels were run for 14–16 h, SSCP gels at constant power
(6–8 W) and heteroduplex gels at constant voltage (700
V). Gels were vacuum dried and exposed for 12–24 h to
a Kodak X-Omat film (Amersham Pharmacia Biotech).
PCR fragments showing abnormal migration were
cloned. First, 3′-A overhangs were further added to the
PCR products, using Biotools Tth DNA polymerase
(B&M Labs) and dATP (Gibco BRL). The PCR products
were then ligated in a pBluescript-SK (Stratagene) T
vector prepared in the laboratory according to the pro-
tocol described elsewhere (Zhou et al. 1995). After trans-
formation and overnight liquid culture, plasmidDNAwas
purified (Bio Rad Quantum Prep Kit). The inserts were
cycle sequenced (Gibco BRL dsDNA Cycle Sequencing
System) with 33P end-labeled M13-forward and M13-re-
verse primers, and the reactions were run on a denaturing
polyacrylamide sequencing gel. After vacuum drying, the
gels were exposed for 12–24 h to Kodak BioMax MR
film (Amersham Pharmacia Biotech).
Allele-Specific PCR
To detect the A3123G transition in genomic DNA, an
allele-specific primer, FLT4I-3123G (5′-CGCACCCCA-
GTGCATCCG-3′), was used with primer FLT4I-13. This
primer pair produces a specific band of 180 bp only for
the allele with a G in position 3123 of the cDNA. Primer
FLT4I-12 was also added to the PCR mix, to produce a
constant control band of 224 bp with the primer FLT4I-
13. The concentration of each primer was 1 mM and that
of dNTP was 50 mM, and we used 0.5 U Biotools Tth
polymerase (B&M Labs) in a final volume of 50 ml. The
cycling conditions were as follows: 95C for 5 min; 35
cycles of 94C for 30 s, 64C for 30 s, and 72 for 30 s;
and 72C for 10 min. PCR fragments were resolved on
a 3% Metaphor agarose gel (FMC Bioproducts).
Phosphorylation Analysis of Wild Type (WT) and
H1035R Mutant VEGFR3
To analyze the phosphorylation of theWT andmutant
VEGFR3 receptors, we used the long form of human
VEGFR3 cDNA cloned into pcDNA3.1/Z() vector
backbone (Invitrogen) (Korpelainen et al. 1999). For
H1035R mutant receptor expression vector, the corre-
sponding ArG mutation at nucleotide 3123 of cDNA
was generated by the GeneEditor in vitro Site-Directed
Mutagenesis System (Promega), using the oligonucleo-
tide 5′-AAGTGCATCCGCAGAGACCTG-3′.
To study phosphorylation of the corresponding mu-
tant VEGFR3, the plasmids encoding WT and mutant
VEGFR3 were transfected into subconfluent 293T cells,
using the calcium phosphate method and 1:0, 3:1, 1:
1, 1:3 and 0:1 ratios of WT to mutant plasmid. The
cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% FCS (Gibco BRL), glutamine,
and antibiotics. An empty vector was used for mock
transfections. After 36 h, the cell monolayers were
washed twice with cold PBS containing 2 mM vanadate
and 2 mM phenylmethylsulfonyl fluoride (PMSF) and
were lysed into PLCLB buffer (150 mM NaCl, 5% glyc-
erol, 1% Triton X-100, 1.5 M MgCl2, and 50 mM He-
pes, pH 7.5) containing 2 mM Vanadate, 2 mM PMSF,
and 0.07 U/ml Aprotinin. The lysates were centrifuged
for 10 min at 19,000 g, and the supernatants were in-
cubated for 2 h on ice with 2 mg/ml of monoclonal anti-
VEGFR3 antibodies (9D9f9) (Jussila et al. 1998). The
immunocomplexes were incubated with protein A se-
pharose (Pharmacia) for 45 min with rotation at 4C.
The sepharose beads were washed three times with cold
PLCLB buffer (containing 2 mM vanadate and 2 mM
PMSF), analyzed by 7.5 % SDS-PAGE, and transferred
to a nitrocellulose filter (Protran Nitrocellulose, Schlei-
cher & Schuell), using semidry transfer apparatus. After
blocking with 5% BSA in TBS-T buffer (10 mM Tris
pH 7.5, 150 mMNaCl, and 0.1 % Tween 20), the filters
were incubated with the phosphotyrosine-specific pri-
mary antibodies (Upstate Biotechnology), followed by
biotinylated goat anti-mouse immunoglobulins (Dako)
and biotin-streptavidin horseradish peroxidase (HRP)
complex (Amersham). The bands were visualized by the
enhanced chemiluminescence method. The filters were
stripped with occasional agitation in 100 mM 2-mer-
captoethanol, 2% SDS, and 62.5 mM Tris-HCl, pH 6.7,
for 30 min at 55C, washed with TBS-T, blocked, and
analyzed for the presence of VEGFR3, using the 9D9f9
antibodies and HRP-conjugated rabbit anti-mouse im-
munoglobulins (Dako).
Results
The family identified showed autosomal dominant in-
heritance with high penetrance (fig. 1A). Linkage anal-
ysis was performed with microsatellite markers located
around the VEGFR3 gene, in the 5q34-q35 region. The
marker results for D5S1354 and D5S2006 were fully
informative for linkage, as well as for the VEGFR3 in-
tragenic polymorphism (fig. 1B and 1C). For these three
markers, the LOD scores were 1.8 at recombination frac-
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Figure 2 Autoradiogram showing sequences of two clones cor-
responding to wild-type (W) and mutant (M) alleles in individual I.1.
Small letters, intronic sequence; capital letters, exonic sequence. * =
mutation.
Figure 3 Effect of H1035R mutation on tyrosyl autophosphor-
ylation of VEGFR3. Expression plasmids for WT and mutant VEGFR3
were transfected into 293T human embryonic kidney cells (lanes 1:0
and 0:1, respectively) or cotransfected using 3:1, 1:1, and 1:3 ratios of
WT to mutant plasmid. Receptor phosphorylation was analyzed from
VEGFR3 immunoprecipitates by western blotting using antiphospho-
tyrosine antibodies (P-Tyr, upper part). Total amount of receptor protein
is shown in VEGFR3 western blotting (lower part). Sizes on the right
correspond to four different forms of VEGFR3 (see text).
tion (v) 0 with 100% penetrance and 1.68 at withv = 0
90% penetrance. These are the maximum LOD scores
for this family.
The exons corresponding to the intracellular part of
the protein were screened for mutations with SSCP and
heteroduplex analysis. A shift was observed in affected
individuals for the PCR fragment corresponding to exon
21. This fragment was reamplified from genomic DNA
of individual I.1 and cloned into a T vector. Six cloned
fragments were sequenced, revealing the presence of an
ArG transition, visible on both strands in two clones at
nucleotide 3123 of the cDNA (Genbank accession num-
ber X68203) (fig. 2). This nucleotide change corresponds
to a histidine-to-arginine substitution in the catalytic loop
of the VEGFR3 receptor tyrosine kinase (residue 1035
of the protein, Swissprot accession number P35916).
With an allele-specific PCR, we checked the cosegrega-
tion of this substitution with the disease in the family
(fig. 1D). Similarly, we checked that this substitution was
not present in 92 control individuals (184 alleles) of
mixed European origin (data not shown).
To test whether the single amino acid substitution iden-
tified in the family with lymphedema alters VEGFR3
function, the corresponding mutant receptor cDNA was
generated in VEGFR3 expression vector by site-directed
mutagenesis and analyzed by transient transfection. Un-
der these conditions, overexpression results in ligand-in-
dependent dimerization and activation of the receptor
tyrosine kinase, thus allowing its transphosphorylation
to be studied. Transfections were made using 1:0, 3:1,
1:1, 1:3, and 0:1 ratios of WT and H1035R mutant
VEGFR3 plasmids (fig. 3). The effect of the mutation on
VEGFR3 tyrosyl phosphorylation was analyzed by im-
munoprecipitation with anti-VEGFR3 monoclonal an-
tibodies followed by western blotting with antiphospho-
tyrosine antibodies (P-Tyr). In this analysis, the mature
full-length VEGFR3 shows as a 195-kD polypeptide
band, and smaller amounts of the VEGFR3 polypeptides
of 175 kD and 125 kD represent the partially glycosy-
lated precursor and the proteolytically processed receptor
subunit chain containing the tyrosine kinase domain (Pa-
jusola et al. 1994). In addition, minor amounts of a 210-
kD form of VEGFR3 were observed in all samples. This
form may be generated by additional glycosylation of the
mature protein. No tyrosyl phosphorylation of the
H1035R VEGFR3 was detected, whereas the WT recep-
tor was strongly phosphorylated (fig. 3).Moreover, phos-
phorylation of the total receptor protein decreased with
increasing amount of mutant vector transfected. Expres-
sion of equal amounts of the VEGFR3 protein was con-
firmed by immunoblotting with antibodies directed to-
ward the extracellular domain of VEGFR3.
Discussion
Using four multigeneration families with inherited con-
genital lymphedema, Ferrell et al. (1998) obtained a peak
multipoint LOD score of 10 at marker D5S1354. They
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Figure 4 A, Amino acid sequence alignment for seven different
human tyrosine-kinase receptors. Conserved catalytic loop residues are
highlighted with gray background. F = mutated histidine (H1035R).
D = residue mutated in KIT causing piebaldism (RrG). * = catalytic
aspartate. B, Crystal structure of VEGFR2, a tyrosine kinase receptor
homologous to VEGFR3. Histidine residue mutated in VEGFR3 re-
ceptor of patients with lymphedema shown in black. The kinase ac-
tivation loop was disordered in the crystal and is not shown.
analyzed the cDNA sequence of the vascular endothelial
growth factor receptor-3 gene (VEGFR3, FLT4) and
found a P1114L substitution in one of the families. This
family, however, was not big enough to be informative
for linkage, and no putative mutations were found in the
families with linkage for the parts of the gene analyzed.
One family was recombinant for 5q34-q35, thus sug-
gesting the existence of another gene responsible for early-
onset lymphedema.More recently, another study has been
published establishing a genetic linkage of congenital lym-
phedema with 5q35.3, with a combined multipoint LOD
score of 16.55 (Evans et al. 1999). Thus, a gene causing
congenital hereditary lymphedema maps to the distal part
of chromosome 5q and could be VEGFR3 (FLT4).
We describe the identification of a two-generation
family with five individuals affected by congenital lym-
phedema. This family also showed linkage to 5q34-q35,
and an A3123G transition corresponding to an
H1035R substitution was identified in the affected fam-
ily members. This transition was not seen in the genomic
DNA of 92 control individuals. The substituted histi-
dine is conserved in protein tyrosine kinases and in
many serine/threonine kinases (fig. 4A; see Hanks and
Hunter [1995] for a review on protein kinases), sug-
gesting a very important structural and/or functional
role. It is the first residue of the consensus sequence
HRDLAARN, the central part of the catalytic loop
of VEGFR3, with the aspartate residue considered to
be the key catalytic residue. The position of the mutated
residue is shown in the three-dimensional structure of
the kinase domain of VEGFR2 homologous receptor
(fig. 4B) (McTigue et al. 1999). For the part of the
protein modeled, this receptor presents 77% identity
with VEGFR3 at the amino acid level, with no insertions
or deletions, and is thus likely to adopt a very similar
structure. Of interest, mutation of the adjacent arginine
to a glycine in the KIT (mast/stem cell growth factor
receptor [MIM 172800]) (Spritz et al. 1993). For all
these reasons, we thought that the H1035R mutation
was likely to cause an impairment of VEGFR3 function.
In fact, our in vitro expression studies showed that
the H1035R VEGFR3 has lost its autophosphorylation
capacity. The H1035R mutation is located in the cat-
alytic domain of VEGFR3, not in a region of tyrosyl
autophosphorylation sites. Thus, the loss of autophos-
phorylation capacity by H1035R indicates loss of ty-
rosine kinase activity, rather than lack of kinase site
recognition, and lymphedema is caused by lack of suf-
ficient VEGFR3 signaling. Since the disorder is inherited
as an autosomal dominant trait with high penetrance,
it seems to be enough to lose the tyrosine kinase activity
of one of the copies of the receptor. However, it is pos-
sible that, in the affected endothelia, additional alter-
ation in VEGFR3 signaling occurs. This will be inter-
esting to test when affected tissue becomes available
from a patient with a verified VEGFR3 mutation.
An interesting aspect of this family is the appearance
of mild specific facial features in the four affected mem-
bers of the youngest generation. Each of the four had
a flat, broad nasal bridge and epicanthic folds. This has
not been reported for any of the other families with
linkage to 5q34-q35 and thus could be specific for this
family, and perhaps for this mutation. However, these
facial features are seen in several other syndromes with
edema (Opitz 1986).
VEGFR3 is not the only mutated gene causing lym-
phedema. Since one family with early-onset lymphed-
ema has been shown to be recombinant in 5q34-q35
(Ferrell et al. 1998), a second genemust exist.Moreover,
lymphedema with distichiasis—abnormal hairs arising
from meibomian glands in the inner eyelid—has been
mapped to chromosome 16q24.3 (Mangion et al.
1999). However, the linked interval of 16 cM does not
contain any obvious candidate gene. Whether the prod-
ucts of these other genes function with VEGFR3 or in
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another pathway is not known. In addition, the cause
of lymphedema in syndromes such as Turner or Noonan
still needs to be discovered.
Finally, identification of VEGFR3 as the causative
gene for hereditary congenital lymphedema might lead
to some advances in the treatment of the disorder. Lym-
phedema is characterized by hypoplastic or aplastic lym-
phatic channels. Thus, loss of adequate VEGFR3 sig-
naling seems to cause diminished or delayed devel-
opment of lymphatic channels. On the contrary, over-
expression of the ligand VEGFC in the skin induces
hyperplasia of the lymphatic channels in transgenic
mice. Although mice and humans differ (e.g. mice with
loss of one Vegfr3 allele do not develop apparent pe-
ripheral lymphedema), local VEGFC supplementation
might ameliorate the condition.
Note added in proof.—While this article was in press,
similar results were published by Karkkainen et al. (2000
[Nat Genet 25:153–159]).
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